Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
First Claim
1. A method of treating type 2 diabetes mellitus in a subject having a baseline hemoglobin A1c (HbA1c) % of greater than 10.0% comprising providing the subject a continuous delivery of a dose of at least 20 mcg/day of an exenatide from an osmotic delivery device, wherein the substantial steady-state delivery of the exenatide from the osmotic delivery device is continuous over an administration period of at least about 1 month, wherein the method produces a decrease in the subject'"'"'s HbA1c % of at least 2% after implantation of the osmotic delivery device in the subject, relative to the subject'"'"'s baseline HbA1c %, and wherein the decrease in the subject'"'"'s HbA1c % is achieved within 13 weeks after implantation of the osmotic delivery device.
5 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.
738 Citations
23 Claims
- 1. A method of treating type 2 diabetes mellitus in a subject having a baseline hemoglobin A1c (HbA1c) % of greater than 10.0% comprising providing the subject a continuous delivery of a dose of at least 20 mcg/day of an exenatide from an osmotic delivery device, wherein the substantial steady-state delivery of the exenatide from the osmotic delivery device is continuous over an administration period of at least about 1 month, wherein the method produces a decrease in the subject'"'"'s HbA1c % of at least 2% after implantation of the osmotic delivery device in the subject, relative to the subject'"'"'s baseline HbA1c %, and wherein the decrease in the subject'"'"'s HbA1c % is achieved within 13 weeks after implantation of the osmotic delivery device.
Specification